Independent GLP-1 & semaglutide coverage
Clear, sourced information on semaglutide and GLP-1 medications
Product comparisons, industry news, and regulatory tracking for Ozempic, Wegovy, Mounjaro, and the broader GLP-1 category — written for readers who want the sourcing, not the hype. Not a pharmacy. Not medical advice.
Product Reviews
Comparisons and device breakdowns for GLP-1 medications.
Why GLP-1 Drug Labels Carry a Thyroid Tumor Warning, and What Human Studies Show
Every long-acting GLP-1 label in the U.S. opens with a boxed warning about thyroid C-cell tumors. Here's where that warning came from, why researchers think rodents and humans may differ, and what large observational studies have found so far.
5 min read
What the GHK-Cu Research Actually Shows, and Where the Evidence Runs Thin
GHK-Cu has a long laboratory record but a very small human one. This explainer walks through the animal work, the handful of controlled human trials, and why the gap between them matters when reading claims about the copper peptide.
5 min read
What Glucagon Does, and Why Retatrutide and Survodutide Activate Its Receptor
Glucagon is best known for raising blood sugar, which makes it an unlikely ingredient in weight-management drugs. Here's what the hormone does naturally, why developers added glucagon receptor activity to retatrutide and survodutide, and what the evidence does and doesn't show.
5 min readNews & Insights
What's moving in the GLP-1 industry — pipeline, coverage, supply.
A 503B Compounder Recalls Tirzepatide Vials Over Sterility Assurance
Apothecary Pharma, a North Carolina outsourcing facility, has recalled 22 vials of compounded tirzepatide nationwide, citing a lack of assurance of sterility. The FDA classified the recall as Class II.
3 min read
Verdiva Ends a Phase 2 Trial of Its Weekly GLP-1 Pill as a Maintenance Option
Verdiva Bio has terminated a Phase 2 study testing once-weekly oral ecnoglutide (VRB-101) for keeping weight off after injectable semaglutide or tirzepatide. The company cited a business decision, not safety, and says the drug remains in development.
3 min read
EU Regulators Recommend Lilly's Foundayo Pill for Weight Management and Type 2 Diabetes
On October 15, 2026, the EMA's human medicines committee adopted a positive opinion for Foundayo (orforglipron), a once-daily oral GLP-1 tablet. The European Commission still has to make the final authorisation decision.
4 min readPolicy & Regulation
How the US, EU, and China regulate GLP-1 medications.
How Generic GLP-1 Drugs Get Approved: The ANDA Pathway for Peptides
Generic liraglutide reached U.S. pharmacies through the abbreviated generic-drug pathway, not the biosimilar route. In July 2026 the FDA revised its draft recommendations for generic semaglutide and tirzepatide as well.
4 min read
The FDA's GLP-1 Ingredient 'Green List': How Import Alert 66-80 Works
Since September 2025, imported GLP-1 active ingredients can be detained at the U.S. border unless their manufacturer appears on an FDA green list, the reverse of the red-list approach many import alerts use.
4 min readSwitzerland: Swissmedic Approval and Specialty List Rules for GLP-1 Weight-Management Drugs
Swissmedic has approved Wegovy and Mounjaro for weight management, but basic health insurance pays only under strict, time-limited Specialty List conditions set by the Federal Office of Public Health.
4 min read